Psychiatric and behavioral concerns of perampanel with concomitant levetiracetam in children with epilepsy
Epilepsy & Behavior · 2024
DOI: 10.1016/j.yebeh.2024.109740 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epilepsy & Behavior, 2024. Verfasst von Jon Soo Kim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Chungbuk National University Hospital, Cheongju, Republic of Korea. Hauptthemen laut MEDLINE: Levetiracetam, Anticonvulsants, Epilepsy, Pyridones. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
PURPOSE: Perampanel (PER) is expanding the therapeutic scope for pediatric epilepsy owing to its efficacy and favorable safety profile. However, concerns about psychiatric and behavioral adverse events (PBAEs) in combination therapy with levetiracetam (LEV) continue to contribute to hesitation in its prescription. We investigated the risk profiles for PBAEs when adding PER to pediatric epilepsy treatment and analyzed the differences according to the presence of concomitant LEV. METHODS: We retrospectively reviewed the medical records of children aged 4-18 years with epilepsy who were prescribed PER as adjunctive therapy from March 2016 to February 2023. We compared the occurrence and management of PBAEs between the PER without LEV and PER with LEV groups. The risk factors for PBAEs were also analyzed. RESULTS: Ninety-four patients (53 boys and 41 girls) were included in this study. The median age of total patients at the time of adding PER was 14.9 years (12.3-16.4 years), and 53 patients (56.4 %) had concomitant LEV. Forty-seven PBAEs occurred in 34 patients (36.2 %), with no significant differences depending on whether concomitant LEV is present or not. The most common PBAEs were aggression (14.9 %), irritability (9.6 %), affect lability (7.4 %), and acute psychosis (6.4 %). PBAEs occurred at a lower dosage (2-6 mg/day) in 70.6 % of the patients. In addition, 73.5 % of patients with PBAEs continued PER treatment by follow-up observation or by reducing the PER dosage. No risk factors, such as the presence of concomitant LEV or lamotrigine, any comorbid conditions, higher PER dosage (8-12 mg/day), two or more concomitant anti-seizure medications, and younger age (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Chungbuk National University Hospital, Cheongju, Republic of Korea.
- Department of Pediatrics, Chungbuk National University Hospital, Cheongju, Republic of Korea; Department of Pediatrics, Chungbuk National University, College of Medicine, Cheongju, Republic of Korea.
- Department of Emergency Medicine, Daejeon Eulji Medical Center, Eulji University, Daejeon, Republic of Korea.
- Department of Pediatrics, Chungbuk National University Hospital, Cheongju, Republic of Korea. Electronic address: hyewonwoo@gmail.com.
Zitieren
APA
Kim, J. S., Kim, W. S., Sung, W. Y., & Woo, H. (2024). Psychiatric and behavioral concerns of perampanel with concomitant levetiracetam in children with epilepsy. Epilepsy & Behavior. https://doi.org/10.1016/j.yebeh.2024.109740
Vancouver
Kim JS, Kim WS, Sung WY, Woo H. Psychiatric and behavioral concerns of perampanel with concomitant levetiracetam in children with epilepsy. Epilepsy & Behavior. 2024. doi:10.1016/j.yebeh.2024.109740
BibTeX
@article{Kim2024,
author = {Kim, Jon Soo and Kim, Won Seop and Sung, Won Young and Woo, Hyewon},
title = {Psychiatric and behavioral concerns of perampanel with concomitant levetiracetam in children with epilepsy},
journal = {Epilepsy & Behavior},
year = {2024},
doi = {10.1016/j.yebeh.2024.109740}
}
EUVIMED